RASSF1A methylation as a biomarker for detection of colorectal cancer and hepatocellular carcinoma

Figure 1 RASSF1A methylation rate in plasma. A: RASSF1A methylation rate in plasma of colorectal cancer (CRC), colorectal polyps and T1-T4 stage of CRC; B: RASSF1A methylation rate in plasma of hepatocellular carcinoma (HCC), liver cirrhosis and T1-T4 stage of HCC. CRC: Colorectal cancer; CRP: Colorectal polyps; HCC: Hepatocellular carcinoma; LC: Liver cirrhosis.

Figure 2 Diagnostic value evaluation of RASSF1A methylation rate in plasma for discriminating colorectal cancer, colorectal polyps, hepatocellular carcinoma, and liver cirrhosis. A: Colorectal cancer and colorectal polyps; B: Hepatocellular carcinoma and liver cirrhosis.

Figure 3 Diagnostic value evaluation of RASSF1A methylation rate in plasma for discriminating T1-T4 stage colorectal cancer and colorectal polyps. A: T1 stage colorectal cancer (CRC) and colorectal polyps (CRP); B: T2 stage CRC and CRP; C: T3 stage CRC and CRP; D: T4 stage CRC and CRP.

Figure 4 Diagnostic value evaluation of RASSF1A methylation rate in plasma for discriminating T1-T4 stage hepatocellular carcinoma and liver cirrhosis. A: T1 stage hepatocellular carcinoma (HCC) and liver cirrhosis (LC); B: T2 stage HCC and LC; C: T3 stage HCC and LC; D: T4 stage HCC and LC.